Health / Medical Topics |
Oncotype DX breast cancer assay
Pronunciation
Definition 1
A test that is used to help predict whether breast cancer will spread to other parts of the body or come back. The test looks at the activity of 21 different genes in breast cancer tissue of women who have early-stage breast cancer that is estrogen receptor positive and has not spread to the lymph nodes. If there is a high risk that the cancer will spread or come back, it may be used to help plan treatment with anticancer drugs. Also called 21-gene signature. (NCI Dictionary)
Definition 2
A diagnostic assay that quantifies the likelihood of breast cancer recurrence in women with newly diagnosed, early stage breast cancer. In addition to predicting distant disease recurrence, Oncotype DX also assesses the benefit from certain types of chemotherapy. The assay, performed using formalin-fixed, paraffin-embedded tumor tissue, analyzes the expression of a panel of 21 genes and the results are provided as a Recurrence Score (0-100). The gene panel was selected and the Recurrence Score calculation was derived through extensive laboratory testing and multiple independent clinical development studies. Oncotype DX is validated for use in breast cancer patients whose disease is newly diagnosed, stage I or II, node-negative, estrogen receptor-positive and who will be treated with tamoxifen. (NCI Thesaurus)